| Todd V Clark, MD | |
|
250 Fountain Ct, Attn: Lauren Bryant, Lexington, KY 40509-1888 | |
| (859) 263-4444 | |
| (859) 254-1814 |
| Full Name | Todd V Clark |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Location | 250 Fountain Ct, Lexington, Kentucky |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205078664 | NPI | - | NPPES |
| 000000612211 | Other | ANTHEM BLUE CROSS & BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 42806 (Kentucky) | Primary |
| Entity Name | Central Kentucky Dermatology Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124741780 PECOS PAC ID: 2860869351 Enrollment ID: O20221114001903 |
News Archive
Researchers have taken a critical step in understanding how allergic reactions occur after identifying a genetic signature for regulation of a key immune hormone, interleukin (IL-13).
Two new studies by scientists at Scripps Research are bringing Ebola virus's weaknesses into the spotlight, showing for the first time exactly how human and mouse antibodies can bind to the virus and stop infection-not only for Ebola virus, but for other closely related pathogens as well.
Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.
Young people's exposure to alcohol advertisements on television could be greatly reduced if alcohol companies improved their use of so-called no-buy lists, according to a study in the January issue of the Journal of Studies on Alcohol and Drugs.
Before humans can benefit from new drug therapies and nutritional additives, scientists test their safety and efficacy in animals, typically mice and rats.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Todd V Clark, MD 250 Fountain Ct, Attn: Lauren Bryant, Lexington, KY 40509-1888 Ph: (859) 263-4444 | Todd V Clark, MD 250 Fountain Ct, Attn: Lauren Bryant, Lexington, KY 40509-1888 Ph: (859) 263-4444 |
News Archive
Researchers have taken a critical step in understanding how allergic reactions occur after identifying a genetic signature for regulation of a key immune hormone, interleukin (IL-13).
Two new studies by scientists at Scripps Research are bringing Ebola virus's weaknesses into the spotlight, showing for the first time exactly how human and mouse antibodies can bind to the virus and stop infection-not only for Ebola virus, but for other closely related pathogens as well.
Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.
Young people's exposure to alcohol advertisements on television could be greatly reduced if alcohol companies improved their use of so-called no-buy lists, according to a study in the January issue of the Journal of Studies on Alcohol and Drugs.
Before humans can benefit from new drug therapies and nutritional additives, scientists test their safety and efficacy in animals, typically mice and rats.
› Verified 1 days ago
Charlie Becknell, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 250 Fountain Ct, Lexington, KY 40509 Phone: 859-263-4444 Fax: 859-254-1814 | |
Leigh Ann Carter Beard, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 715 Shaker Dr Ste 132, Lexington, KY 40504 Phone: 859-288-5004 Fax: 859-288-5007 | |
Dr. Dana Black, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3475 Richmond Rd, Suite 200, Lexington, KY 40509 Phone: 859-296-4400 Fax: 859-296-4300 | |
Dr. Sean A Marzolf, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 250 Fountain Ct, Lexington, KY 40509 Phone: 859-263-4444 Fax: 859-263-6781 | |
Dr. Tandy Sutton Repass, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3475 Richmond Rd Ste 200, Lexington, KY 40509 Phone: 859-296-4400 | |
Dr. Clifton Smith, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 177 Burt Rd, Lexington, KY 40503 Phone: 859-276-1511 Fax: 859-276-3373 | |
Deborah K Phillips, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4071 Tates Creek Centre Dr Ste 202, Lexington, KY 40517 Phone: 859-226-0206 |